Novel polypeptides
AssigneeAlligator Bioscience AB
InventorsAnna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
Life of this patent
Estimating the term…
Abstract
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of targeting a dendritic cell, and a second binding domain, designated B2, which is capable of targeting a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
Claims109
A bispecific polypeptide comprising:
- (i) a first binding domain, designated B1, capable of targeting a dendritic cell (DC);
- and
- (ii) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
- wherein the bispecific polypeptide is capable of inducing
- (a) tumour-localised activation of dendritic cells, and/or
- (b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
- for use in treating a patient with a neoplastic disorder comprising tumour cells and/or preventing a neoplastic disorder comprising tumour cells in a patient;
- wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.
A method of treating a neoplastic disorder in a patient and/or preventing a neoplastic disorder comprising tumour cells in a patient and/or diagnosing a neoplastic disorder comprising tumour cells in a patient, comprising the step of administering to the subject an effective amount of a bispecific polypeptide comprising:
- (i) a first binding domain, designated B1, capable of targeting a dendritic cell (DC);
- and
- (ii) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
- wherein the bispecific polypeptide is capable of inducing
- (a) tumour-localised activation of dendritic cells, and/or
- (b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
- wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.
A use of a bispecific polypeptide comprising:
- (iv) a first binding domain, designated B1, capable of targeting a dendritic cell (DC);
- and
- (v) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
- wherein the bispecific polypeptide is capable of inducing
- (a) tumour-localised activation of dendritic cells, and/or
- (b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
- in the preparation of a medicament treating a neoplastic disorder in a patient and/or preventing a neoplastic disorder comprising tumour cells in a patient;
- wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.
The bispecific polypeptide or method or use according to claim 12, wherein the extracellular vesicles are exosomes.
The bispecific polypeptide or method or use according to any one of claims 33-56, wherein the antibody comprises one or more mutation pairs each comprising two functionally compatible mutations.
An isolated nucleic acid molecule encoding a bispecific polypeptide according to any one of the preceding claims, or a component polypeptide chain thereof.
A method of producing a DC-TAA bispecific polypeptide, the method comprising:
- (a) measuring a tumour cell or tumour cell-derived extracellular vesicle to determine density of a tumour-cell associated antigen
- (b) if the density is above 30,000 on tumour cell (for example, 100,000 on tumour cell), then classifying the TAA as a suitable target for a DC-TAA bsAb
- (c) producing a bispecific polypeptide capable of targeting the TAA, and also capable of targeting a DC.
The bispecific polypeptide according to any one of claim 1, 4-68 or 95-101 or the method according to any one of claim 2, 4-68 or 95-101 or the use according to any one of claim 3-68 or 95-1019, wherein the polypeptide is for use in combination with one or more additional therapeutic agents.
The bispecific polypeptide or method or use according to claim 103, wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-L1, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, VISTA and KIR.
A bispecific polypeptide substantially as described herein with reference to the description and figures.
A polynucleotide substantially as described herein with reference to the description and figures.
A pharmaceutical composition substantially as described herein with reference to the description and figures.
Use of a bispecific polypeptide substantially as described herein with reference to the description and figures.
A method of treatment substantially as described herein with reference to the description and figures.
Dependencies are inferred from the claim text.